



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/576,331	Brian Edward Jones	GC8192USB

INTERNATIONAL APPLICATION NO.
-------------------------------

PCT/US04/39066

Kamrin T. MacKnight  
 Genencor International, Inc.  
 925 Page Mill Road  
 Palo Alto, CA 94304-1013

RECEIVED

JAN - 4 2007

Patent  
 Department

I.A. FILING DATE	PRIORITY DATE
11/19/2004	11/19/2003

CONFIRMATION NO. 7214

371 FORMALITIES LETTER



\*OC000000021677376\*

Date Mailed: 12/27/2006

### NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 04/18/2006
- Copy of the International Search Report filed on 04/18/2006
- Preliminary Amendments filed on 08/29/2006
- U.S. Basic National Fees filed on 04/18/2006
- Priority Documents filed on 04/18/2006
- Specification filed on 04/18/2006
- Claims filed on 04/18/2006
- Abstracts filed on 04/18/2006
- Drawings filed on 04/18/2006

MC 819-2-US/B  
 File: KM  
 Atty: 2-27-07  
 Due Date: 7-27-07  
 Final Date: 7-27-07  
 Type: MP

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

#### SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$130** for a Large Entity:

- **\$130 Surcharge.**

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

**For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:**

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

**ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.  
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

**If you are not using EFS-Web to submit your reply, you must include a copy of this notice.**

VONDA M WALLACE

Telephone: (703) 308-9140 EXT 225

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/576,331	PCT/US04/39066	GC8192USB

FORM PCT/DO/EO/905 (371 Formalities Notice)

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: July 16, 2007

By: Mari Kleineidam  
Mari Kleineidam

**PATENT**  
**Docket No. GC819-2-US/B**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of	)	Group Art Unit: Unassigned
	)	
JONES <i>et al.</i>	)	Examiner: Unassigned
	)	
Serial No.: 10/576,331	)	
	)	
Filed: April 18, 2006	)	
	)	
For: SERINE PROTEASES, NUCLEIC	)	
ACIDS ENCODING SERINE	)	
ENZYMES AND VECTORS AND	)	
HOST CELLS INCORPORATING	)	
SAME	)	
	)	

**RESPONSE TO THE NOTIFICATION OF MISSING**  
**REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES**  
**DESIGNATED/ELECTED OFFICE (DO/EO/US)**

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In complete response to the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) mailed December 27, 2006, please find:

[X] Three (3) sets of the Combined Declaration and Power of Attorney signed by the inventor(s) and the surcharge of \$130.00 as set forth in 37 C.F.R. § 1.16(e);

[X] Petition for a five-month Extension of Time;

07/19/2007 GFREY1 00000038 071048 10576331

02 FC:1617 130.00 DA

GC819-2-US/B T-MP 371

- ☐ [ ] Revocation & New Power of Attorney;
- ☐ [ ] Preliminary Amendment;
- ☒ [X] Statement of Sameness;
- ☒ [X] Paper copy of Sequence Listing;
- ☒ [X] Diskette copy of Sequence Listing;
- ☐ [ ] Request for Use of an Identical Computer Readable Form in Another Application Under 37 CFR § 1.821(e);
- ☐ [ ] Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (copy of Notice to be returned with response);
- ☒ [X] Form PCT/DO/EO/905 (371 Formalities Notice); and
- ☐ [ ] Other: \_\_\_\_\_
- ☒ [X] Charge \$2,290.00 to Deposit Account No. 07-1048.

The Director is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC819-2-US/B). A duplicate of this paper is enclosed.

Respectfully submitted,

Dated: July 16, 2007

  
Kamrin T. MacKnight  
Reg. No. 38,230

Danisco US Inc., Genencor Division  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel.: 650-846-5838  
Fax: 650-845-6504